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a b s t r a c t
Alpha-herpesviruses can produce more severe infections in non-natural host species than in their natural
host. Isolates of the baboon alpha-herpesvirus Papiine herpesvirus 2 (HVP2) are either very neurovirulent
in mice (subtype nv) or non-virulent (subtype ap), but no such difference is evident in the natural
baboon host. Comparative genome sequencing was used to identify subtype-speciﬁc sequence differ-
ences (SSDs) between HVP2nv and HVP2ap isolates. Some genes were identiﬁed that despite exhibiting
sequence variation among isolates did not have any SSDs, while other genes had comparatively high
levels of SSDs. Construction of genomic recombinants between HVP2nv and HVP2ap isolates mapped the
mouse neurovirulence determinant to within three genes. Construction of gene-speciﬁc recombinants
demonstrated that the UL39 ORF is responsible for determining the lethal neurovirulence phenotype of
HVP2 in mice. These results demonstrate that differences in a single viral gene can determine the
severity of herpesvirus infection in a non-natural host species.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Zoonotic infections are a major public health concern and
constitute the majority of ‘emerging infectious diseases’. Despite
the extremely serious nature of many zoonotic infections, it is
likely that the vast majority of human exposures to nonhuman
viruses result in very mild or abortive infections in which the virus
is never able to establish itself in the human host. Understanding
why some viruses are able to cross the species barrier and produce
serious disease in non-natural hosts while others cannot is central
to being able to treat and even prevent such infections.
Macacine herpesvirus 1 (monkey B virus; BV) is an α-herpes-
virus that is indigenous in macaque monkeys (Macaca spp.). The
BV genome is orthologous to that of herpes simplex virus type 2
(HSV2) and the chimpanzee virus (ChHV), having long and short
unique regions (UL and US, respectively) that are each ﬂanked by
repeat sequences (RL and RS, respectively) (Dolan et al., 1998;
Perelygina et al., 2003; Severini et al., 2013). BV also exhibits
substantial antigenic cross-reactivity with HSV (Eberle and
Hilliard, 1995 and Eberle and Black, 1999). In its natural macaque
host BV behaves very much as HSV does in humans: primary
infections are usually asymptomatic, latent infection is established
in sensory neurons, and in response to stress the virus may
reactivate from latency with shedding of infectious virus. In stark
contrast to the self-limiting nature of infections in its natural
macaque host, a very different disease picture results when BV is
transmitted to humans, usually via a monkey bite or scratch
(Davidson and Hummeler, 1960; Elmore and Eberle, 2008; Huff
and Barry, 2003; Weigler et al., 1993). BV invades peripheral
sensory neurons, but instead of establishing a latent infection in
sensory ganglia BV rapidly invades and spreads within the CNS,
ascending the spinal cord to the brainstem and destroying CNS
tissue. Untreated, about 80% of human BV patients die, and
survivors frequently experience progressive neurological sequelae.
Why BV behaves so very differently in macaques vs. humans
remains unknown.
Phylogenetically and antigenically, the α-herpesvirus most
closely related to BV is Papiine herpesvirus 2 (HVP2) (Eberle
et al., 1995; Eberle and Hilliard, 1995; Tyler and Severini, 2006).
The HVP2 genome is orthologous with that of BV, having 85%
sequence identity to BV, a similarly high GþC content (76.5% vs.
74.5% for BV) and a very high GC-codon bias (Tyler and Severini,
2006). HVP2 is indigenous in baboons (Papio spp.) in which it
behaves the same as BV in macaques or HSV in humans (Eberle
et al., 2008). Despite the very close relatedness of BV and HVP2,
there are no known cases of human HVP2 infections. However,
HVP2 does have the potential to produce fatal neurological
infections as evidenced by lethal infection of a colobus monkey
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(Colobus guereza) that bore all the hallmarks of a human BV
infection (Troan et al., 2007). Why BV and HVP2 should be so
very divergent in regard to their apparent neurovirulence in
humans is unknown.
Based on its very close similarity to BV, HVP2 has found use as a
model for BV. While HVP2 isolates are equally pathogenic in their
natural baboon host, testing of 420 HVP2 isolates in mice
revealed that there are only two very distinct phenotypes with
regard to their neurovirulence: either extremely neuroinvasive
and lethal or nonvirulent (Rogers et al., 2003, 2005, 2006).
Neurovirulent HVP2 strains (HVP2nv) rapidly invade the CNS with
destruction of CNS tissue that reﬂects that of BV in humans, while
nonvirulent HVP2 strains (HVP2ap) invade the CNS much less
efﬁciently, do not spread efﬁciently within the CNS, and cause only
limited destruction of CNS tissue (Rogers et al., 2006). Since
mouse-HVP2 neurovirulence is a simple 2-character state model,
it represents an ideal model system in which viral determinants
that facilitate severe cross-species infections can be investigated.
Here we report the results of studies aimed at identifying speciﬁc
gene(s) of HVP2 that determine the lethal neurovirulence of the
virus in a non-natural host species.
Results
Comparative genome sequencing and analysis
Comparison of sequences of closely related viruses to identify
genetic differences that underlie variant phenotypes is a simplistic
approach that may not be effective for a number of reasons. For
example, different mutations, even different mutations within
different genes, may result in a similar phenotype in different
viral isolates. Also, multiple genetic differences may deﬁne a
phenotype. It is even possible that mutations resulting in different
codon usage, changes in non-translated regions of mRNA, or even
varied expression of a gene could alter a phenotype. Assessing
420 strains of HVP2 for neurovirulence in mice revealed only two
very distinct and consistent phenotypes – neurovirulent and
rapidly lethal or non-lethal. Furthermore, the neurovirulence
phenotype of HVP2 strains has correlated 100% with the ability
of an isolate to replicate efﬁciently and suppress the IFN-β
response in PMDF cells (Rogers et al., 2003, 2007, 2009). The lack
of variability in this phenotype among so many HVP2 strains
suggested that there may be only a single, consistent difference
between HVP2nv and HVP2ap strains that underlies the mouse
neurovirulence phenotype. We therefore took the approach of
comparative genome sequencing to determine if this approach
had value in identifying phenotype-deﬁning genetic differences
among herpesvirus isolates.
The complete genome sequence of six HVP2 isolates was
determined which together with the previously published
sequence for strain X313 (Tyler and Severini, 2006) resulted in
genomic sequences for three HVP2nv strains and four HVP2ap
strains. For each coding sequence, nucleotide differences that
resulted in changes in the AA sequence of the encoded protein
were divided into two groups: sequence differences that were the
same in all HVP2ap isolates but were different from HVP2nv
isolates were classiﬁed as SSDs, while those that were present in
one or more isolates but did not correlate with the neurovirulence
subtype were classiﬁed as isolate-speciﬁc differences. To assess the
distribution of types of sequence differences across the HVP2
genome, ORF variation scores were calculated and plotted along
the viral genome map (Fig. 1).
The distribution of SSDs was not uniform along the HVP2
genome; there were fewer SSDs located in genes located in the left
part of the UL region (genes UL4-20) than in the right part of the
UL region or the US region, and overall the US region had a higher
density of SSDs than the UL region. Of the 73 ORFs assessed, 8 had
scores of 0 as they contained no SSDs (UL14, UL15, UL41, UL49.5,
UL53, UL55, US2 and US9). A number of other genes had very low
scores (i.e., only a few subtype-speciﬁc conservative AA substitu-
tions). The ORFs having the highest scores were UL1, UL33, UL39,
UL45, UL56, US4, US5, US8, and US10-12. Gene function was not
associated with a high or low ORF score; groups of genes involved
in similar functions (DNA replication, protein modiﬁcation, reg-
ulatory, capsid structure, DNA packaging, glycoproteins) exhibited
a spectrum of scores ranging from none to very high. We could not
identify any characteristic that related to the level of SSDs in
different genes.
Although only 3–4 genomes of each HVP2 subtype were
sequenced, the above analyses completely eliminated 8 viral genes
(with scores of 0) from possibly inﬂuencing the mouse neuroviru-
lence phenotype of HVP2. There were 11 genes that had only one
SSD resulting in a non-conservative AA change and an additional
11 that had only two. Assuming that such conserved genes are less
likely to underlie the pathogenic phenotype of the virus than are
genes with more SSDs, a total of 30 genes out of the 72 known
genes had a low probability of being a potential determinant of
cross-species neurovirulence.
To determine if additional genome sequences could eliminate
additional genes through greater discrimination between SSDs
and non-SSDs, we focused on a single gene (UL39) that had a
comparatively high ORF variation score of 6 (50 total SSDsþ4
gaps/2985 bp). The UL39 gene sequence was determined for a total
of 12 HVP2 isolates (7 from complete genome sequencing and 5
Fig. 1. ORF variation scores based on SSDs identiﬁed from comparison of 7 HVP2 genomic sequences. Genome sequences were aligned, SSDs identiﬁed and those located
with coding sequences assigned a weighted value as described in the section ‘Materials and methods’ to arrive at an ORF variation score for each gene.
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by PCR/sequencing, 6 of each neurovirulence subtype). DNA
sequences of the UL39 ORF, the 50 intergenic ﬂanking region (413
nucleotides), and the 30 ﬂanking intergenic region (69 nucleotides)
were aligned sequentially, adding one pair of sequences (one of
each subtype) at a time. At each step the total number of
nucleotide sequence differences and the number of these that
were subtype-speciﬁc were tabulated as were gaps (insertions/
deletions) in the aligned sequences. Starting with comparison of
two sequences (one of each subtype), all sequence differences
appear as subtype-speciﬁc (Table 1). As additional sequence pairs
are added to the alignment, the total number of sequence
differences increases, but the ability to discriminate between
isolate-speciﬁc and subtype-speciﬁc differences also increases.
Despite the sequence variation in the UL39 ORF, alignment of only
ﬁve sequence pairs was required before no further reduction in
SSDs occurred. Sequence variation in the UL39 ORF thus appears
associated with the neurovirulence phenotype and is not due to a
high degree of sequence variation among individual HVP2 isolates.
For the two ﬂanking intergenic regions, even fewer sequence pairs
were required before stabilization in the number of SSDs occurred.
Assembling alignments by sequential addition of sequence pairs
using a different order of sequence pairs did have a small effect on
the number of pairs required to reach a stable endpoint in the
number of SSDs; initiating the process using sequences from
isolates most different from each other (strains isolated years
apart at different institutions) resulted in the most rapid identiﬁcation
of ﬁnal SSDs.
Mapping the neurovirulence phenotype with inter-typic
recombinants
While comparative sequencing does appear to have the poten-
tial to reduce the number of potential candidate genes conferring
the cross-species neurovirulence phenotype on HVP2, three gen-
ome pairs was not sufﬁcient to accomplish this goal. As a second
approach to identify a gene(s) responsible for the mouse neuro-
virulence phenotype of HVP2, recombinant viruses were con-
structed. Taking advantage of a unique Xba1 site located in the
UL33 ORF of all HVP2 isolates, recombinant viruses were gener-
ated between two separate pairs of HVP2nv and HVP2ap strains.
An initial set of recombinants (series XX) was made using strains
OU1-76 (HVP2nv) and OU2-5 (HVP2ap) as parental viruses. Viral
DNAs were digested with Xba1, the two DNAs combined, trans-
fected into Vero cells, and infectious virus recovered. Recombi-
nants were identiﬁed by PCR/sequencing of 570 bp spanning the
unique Xba1 site, with sequence differences between the two
parental strains allowing the virus strain origin of sequences on
each side of the Xba1 site to be determined. The genomes of
recombinants were further characterized by PCR/sequencing of
300–500 bp in the UL5, UL51, RL2 and US4 genes to map in a very
broad sense what areas of the genome were derived from which
parental virus. Genome maps of several representative XX recom-
binants are shown in Fig. 2.
A total of 24 XX recombinants were generated. While some of
the recombinants had complete halves of the UL region (UL5–UL33
or UL33–UL51) derived from each parental virus (eg. XX30, XX38,
XX43, XX32, XX71 and XX76 in Fig. 2), other recombinants had
a second recombination point located in one or both halves of the
UL region (eg. XX18 and XX55 in Fig. 2). All recombinants had the
long repeat (RL) regions of only one parental virus. The neuroviru-
lence of 22 XX recombinants was assessed by inoculating mice
with 105 PFU by skin scariﬁcation. Using this virus dose the two
parental strains exhibit very distinct neurovirulence phenotypes in
mice (Rogers et al., 2003). All recombinants tested displayed one of
the two parental neurovirulence phenotypes (Fig. 3 shows results
for the representative recombinants diagramed in Fig. 2). Mice
inoculated with some recombinants rapidly succumbed to lethal
CNS infection, developing hind limb paralysis and death within
5–7 days, while others exhibited minimal lethality (that followed a
more extended development timeframe) or very mild/no clinical
Table 1
Effect of the number of gene sequence pairs on differentiating isolate-speciﬁc from
subtype-speciﬁc sequence differences.
No. seq pairs 50 Intergenic region (413 nuc) UL39 ORF (2973 nuc)
Substitutions Gaps Substitutions Gaps
Total SSD Total SSD Total SSD Total SSD
1 27 27 13 13 75 75 18 18
2 32 24 24 10 81 63 36 15
3 38 20 19 8 93 52 39 6
4 39 20 19 8 101 50 39 3
5 39 20 19 8 104 49 39 3
6 39 20 19 8 105 49 39 3
DNA sequences were aligned sequentially, adding one pair of sequenced at a time
(one ap and one nv). At each step the total number of nucleotide sequence
differences (total) and the number of these that were subtype-speciﬁc differences
(SSD) were tabulated. Gaps (insertions/deletions) in the aligned sequences were
similarly tabulated. The point at which the number of SSDs stabilized is indicated
by numbers in bold.
Fig. 2. Genomic maps of inter-typic HVP2 recombinants. Recombinant HVP2 strains were constructed and the parental origin of UL5, UL51, RL2, US4 and the UL33 ORF on
both sides of the unique Xba1 site in UL33 were determined by sequencing of PCR products. Regions of the genomes derived from the neurovirulent parent are shown in
black and regions from the apathogenic parent virus are in white. Representative recombinants are shown, and are grouped with the parental virus (OU1-76 or OU2-5)
having the same neurovirulence phenotype as indicated at left. Recombinants XX18 and XX55 are representative recombinants having a second recombination point located
between the UL33 and UL51 genes (indicated by gradient coloring).
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signs of CNS infection. All mice surviving to 14 days PI developed
an anti-HVP2 IgG response, conﬁrming that they had been
infected.
To identify HVP2 gene(s) potentially associated with lethal
neurovirulence, genome maps of recombinant viruses (Fig. 2) were
compared with their in vivo neurovirulence phenotype (Fig. 3).
Based on recombinants XX18, XX55 and XX71 it was evident that
the parental virus origin of the US region did not correlate with the
neurovirulence phenotype. Similarly, recombinants XX43, XX55,
XX71 and XX76 indicated that the parental origin of the RL region
did not correlate with neurovirulence. Correlations are more
complicated for the much larger UL region due to secondary
recombination points. However the parental origin of the left half
of the UL region (UL5–UL33) did not correlate with neurovirulence
of recombinants. Recombinants XX32, XX30, XX38, XX43, XX55,
XX71 and XX76 had the entire region between UL5 and UL33
derived from one parental virus, and the parental virus origin of
this region did not correlate with the neurovirulence of the virus.
In contrast recombinants XX30, XX32, XX38, XX43, XX71 and
XX76 all had the right half of the UL region (UL33–UL51) derived
from a single parental virus and the neurovirulence of these
recombinants directly correlated with the parental virus origin of
this region. These results suggest that the gene(s) determining the
murine lethal neurovirulence phenotype lies within the UL33–Ul51
region of the HVP2 genome.
To conﬁrm these results, a second set of recombinants (series
AX) was generated using two different virus strains (HVP2nv
strain X313 and HVP2ap strain A951). Recombinants were gener-
ated, genomes mapped, and neurovirulence assessed as described
above. A total of 20 AX recombinants were tested to assess their
neurovirulence in mice. Once again, neurovirulence did not
correlate with the parental origin of the RL region, the US region,
or the UL1-33 region while the parental virus origin of the UL33–
UL56 region showed 100% correlation with the neurovirulence
phenotype (not shown). From these results we conclude that the
gene(s) underlying the neurovirulence phenotype of HVP2 lies
within the UL33–UL51 region of the genome.
While many recombinants had the majority of each half of the
UL region derived from different parent viruses, 18 recombinants
(11 from XX series, 7 from AX series) had a second recombination
point within the UL33–UL51 region (eg. recombinants XX18 and
XX55 in Fig. 2). To further map the neurovirulence determinant
within this region, PCR/sequence analysis using primer pairs sited
at 5 kbp intervals between UL33 and UL51 were used to spot-
check for the parental virus sequence and so localize the second
recombination point (Fig. 4). Based on the neurovirulence pheno-
type of these recombinants and the location of recombination
Fig. 3. Neurovirulence of inter-typic HVP2 recombinants. Mice were infected with
105 PFU of recombinants by skin scariﬁcation on the hind ﬂank and observed for
14 days. Results for the representative viruses in Fig. 2 are shown here. The RL, US/
RS, and UL1–UL33 regions did not correlate with neurovirulence. In contrast, all
recombinants having the UL33–UL51 region of the genome derived from the
neurovirulent parent virus developed severe neurological infections requiring
euthanasia by 8 days PI while viruses having the UL33–UL51 region derived from
the apathogenic parent virus survived to 14 day PI.
Fig. 4. Localization of the HVP2 murine neurovirulence determinant. The general layout of the HVP2 genome and genes in the right half of the UL region are shown at top.
The parental origin of sequences in all nine recombinants that had a second recombination site between UL33 and UL51 was determined by sequencing of PCR products
generated at approximately 5 kb intervals (indicated by triangles). Sequences from the neurovirulent parent virus are indicated by black and those from the apathogenic
parent virus by white; gray areas represent areas between PCR points in which the second recombination point lies. The neurovirulence phenotype of each virus is indicated
at right. For all nine recombinants, the parental origin of the region of the HVP2 genome between the ends of the UL36 and UL40 genes correlates with the neurovirulence
phenotype.
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points within the UL33–UL51 region of the genome, the neuro-
virulence phenotype was mapped to a 9.31 kbp region extending
from the 50200 bp of the UL36 ORF to the midpoint of the UL39–
UL40 intergenic region.
Identiﬁcation of UL39 as the primary determinant of neurovirulence
While nucleotide sequence differences that alter transcription
of a gene could affect neurovirulence, we initially focused on
differences resulting in a change in the AA sequence of encoded
polypeptides. Focusing on the UL36–UL39/40 intergenic region,
comparative sequence analysis showed that the 50 200 bp of the
UL36 ORF contained no SSDs, eliminating UL36 as a potential
neurovirulence determinant. All three of the remaining coding
sequences (UL37, UL38 and UL39) had SSDs that resulted in
changes of their AA sequences. Alignment of 10 UL37 sequences
identiﬁed a total of 3 subtype-speciﬁc AA differences (2 conserva-
tive and 1 non-conservative) in the 1207 AA alignment (0.2%
subtype-speciﬁc sequence divergence). Similarly, alignment of
10 UL38 sequences identiﬁed only 5 subtype-speciﬁc AA substitu-
tions (2 conservative and 3 non-conservative) in the 457 AA
alignment (1.1% subtype-speciﬁc sequence divergence). In contrast,
comparison of 13 UL39 sequences revealed a total of 38 subtype-
speciﬁc AA substitutions (24 conservative and 14 non-conservative)
along the 989 AA sequence alignment (3.8% subtype-speciﬁc
sequence divergence; see Supplemental material). Based on this,
the UL39 gene seemed to be the most probable candidate gene for
determination of the cross-species neurovirulence phenotype.
To test this prediction, gene-speciﬁc UL39 recombinants were
constructed. Nomenclature used for these recombinants consisted
of an A, N or F [designating the phenotype origin of the UL39 ORF
(apathogenic, neurovirulent, or deletion via replacement with GFP
or RFP, respectively) plus ﬂanking ‘a’ or ‘n’ to designate the
parental phenotype of the ﬂanking genomic sequences. The
UL39 ORF of HVP2ap strain OU2-5 was deleted and replaced with
a GFP expression cassette (mutant aFa), with the parental HVP2ap
UL39 ORF (revertant aAa) or with the HVP2nv UL39 ORF (recom-
binants aNa). A similar set of UL39 mutants was constructed on
the HVP2nv OU1-76 background (designated nFn, nNn and nAn,
respectively). The neurovirulence of the UL39 mutants was then
tested in mice (Fig. 5). Mice infected with the neurovirulent
parental OU1-76 virus or revertant nNn developed initial neuro-
logical symptoms at 4–5 DPI that rapidly progressed to death by
6–7 DPI while mice infected with the apathogenic parental OU2-5
virus or revertant aAa survived, developing only mild neurological
symptoms that improved over time. Infection with mutants lacking
a UL39 ORF (nFn or aFa) failed to produce any neurological
symptoms in infected mice, indicating that UL39 is important for
neurovirulence. Mice infected with two different recombinant
apathogenic viruses carrying the UL39nv ORF (aNa) developed
clinical signs of neurological involvement and died at 7–8 DPI while
two neurovirulent recombinant viruses carrying the UL39ap ORF
(nAn) survived infectionwith only mild neurological symptoms that
improved with time like the parental HVP2ap virus. All survivors
had anti-HVP2 serum IgG, conﬁrming their infection. These results
demonstrate that the UL39 ORF determines the ability of HVP2 to
produce lethal neurological infections in mice. However, the slightly
delayed death of mice infected with the aNa recombinants relative
to WT HVP2nv (1 day) suggests that some factor other than UL39
may affect the rate at which the infection progresses.
Previous studies have shown that the mouse neurovirulence
phenotype of HVP2 strains correlated with their ability to replicate
productively and to suppress an IFN-β response in primary mouse
skin ﬁbroblast cultures (Rogers et al., 2009). Since UL39 deter-
mines lethal neurovirulence in mice, UL39 recombinants were
tested for their ability to replicate in PMDF cultures and to
suppress an IFN-β response.
To assess replication, PMDF cultures were infected at a low MOI
(0.01 PFU/cell), observed daily for plaque formation, and at 96 h PI
infectious virus was quantitated. As previously reported (Rogers
et al., 2007) OU2-5 and revertant aAa formed small foci of
infection by 24 h PI but CPE did not spread with time. Conversely,
OU1-76 and revertant nNn both formed plaques by 24 h PI and
CPE rapidly progressed to involve the entire cell monolayer within
48 h PI. OU2-5 mutants with UL39nv (aNa) also formed plaques
that rapidly spread to destroy the cell cultures by 48 h PI.
In contrast, OU1-76 mutants with UL39 (nAn) initially formed
small plaques by 24 h PI, but these failed to enlarge past 24 h PI.
Consistent with these observations, the two deletion mutants that
lacked a UL39 ORF (aFa and nFn) produced only small initial foci of
infection that failed to enlarge past 24 h PI. Quantitative assess-
ment of infectious virus at 96 h PI reﬂected these observations
(Fig. 6, left). Viruses that could form large plaques produced
signiﬁcantly greater amounts of infectious virus than did viruses
that did not. These results show that UL39 ORF imparts upon the
virus the ability to replicate in primary murine cells, which
correlates with their neurovirulence in mice.
To assess the ability of UL39 mutants to suppress an IFN-β
response by the infected cell, conﬂuent PMDF cultures were
infected and IFN-β excreted into the extracellular medium assayed
by ELISA at 24 h PI (Fig. 6, right). Consistent with previous reports
(Rogers et al., 2009), the parental apathogenic strain OU2-5 and
revertant aAa both induced IFN-β production while the parental
neurovirulent OU1-76 strain and revertant nNn did not
(Po0.001). Both of the neurovirulent mutants carrying the UL39ap
ORF (nAn) also failed to induce an IFN-β response, while apatho-
genic parental recombinants carrying the UL39nv ORF (aNa) did.
This suggests that the ability to suppress an IFN-β response is not
Fig. 5. The UL39 ORF determines neurovirulence of HVP2 in mice. UL39 mutants constructed on the neurovirulent OU1-76 background (designated nXn) are shown at left,
and those on the apathogenic OU2-5 background (designated aXa) are at right. Mice were inoculated by skin scariﬁcation with 105 PFU of virus and observed for 14 days. All
viruses with the UL39nv ORF were neurovirulent while those with the UL39ap ORF or with the UL39 ORF deleted were not pathogenic.
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a function of the UL39 gene, but rather lies elsewhere within the
parental background of the virus. However, the HVP2nv mutant
lacking a UL39 ORF (nFn) consistently produced low levels of IFN-
β, suggesting that UL39 does to some extent suppress the IFN-β
response. The consistently lower level of IFN-β produced by cells
infected with the nFn mutant relative to all HVP2ap mutants
implies that some other factor present in HVP2nv but not in
HVP2ap also has a suppressive effect which, together with that of
UL39, results in complete suppression of the IFN-β response.
Discussion
Advances in genome sequencing technology have made
sequencing of large genomes feasible. This in turn makes possible
comparative analysis of multiple genomic sequences as a means of
identifying sequence differences or genes associated with speciﬁc
phenotypes. This approach has been used to identify nucleotides
changes associated with attenuation of varicella zoster virus
(Peters et al., 2006; Tyler et al., 2007) and to differentiate vaccine
and ﬁeld isolates of BHV1 and to explore the viral origins of
vaccination-associated disease outbreaks (Fulton et al., 2013). Here
we used this approach in an attempt to identify genes of HVP2 that
are associated with extreme neurovirulence in a non-natural host
species.
The very high GþC content of the HVP2 genome (475%)
resulted in less efﬁcient sequencing than for other microbial
agents, so only 6 HVP2 isolates were sequenced. This compara-
tively small number of genome sequences (3 pairs) together with
the greater inter-strain sequence plasticity of simplexvirus gen-
omes as compared to varicellovirus genomes did not allow
identiﬁcation of speciﬁc genes that were associated with the
mouse neurovirulence phenotype. However, a signiﬁcant number
of genes could be eliminated as being associated with the
phenotype by virtue of their lack of any SSDs. Analysis of gene
sequences for one highly variable gene (UL39) indicated that as
few as 6–7 genome pairs would likely provide the power neces-
sary to distinguish all SSDs from isolate-speciﬁc sequence differ-
ences, thereby further narrowing the number of genes potentially
associated with the mouse neurovirulence.
Construction of recombinant viruses has long been used to
identify regions of herpesvirus genomes and to conﬁrm the role of
speciﬁc genes associated with speciﬁc traits. Using this approach
the mouse neurovirulence phenotype was mapped to the UL36–
UL40 region of the HVP2 genome. Applying a comparative
sequence approach to this region of the genome completely
eliminated one ORF and an intergenic region from consideration
and allowed prioritization of the remaining genes as to the
likelihood of their affecting neurovirulence, UL39 being the most
likely candidate. Subsequent construction and testing of UL39-
speciﬁc recombinants conﬁrmed these predictions and validated
the use of predictive comparative sequence analysis.
The UL39 gene encodes the large subunit of the ribonucleotide
reductase (RR) enzyme. RR converts ribonucleotides (CDP, ADP
and GDP) into deoxyribonucleotides for use in DNA synthesis. The
poor replication of UL39-deﬁcient HSV mutants in conﬂuent, non-
dividing cells where intracellular dNTP pools are low (Goldstein
and Weller, 1988; Smith et al., 1998) suggests that the viral RR
functions in vivo by enabling the virus to replicate in non-dividing
cells like neurons. Consistent with this assumption, HSV UL39
mutants do not productively replicate in peripheral neural tissue
but do establish latent infections (Cameron et al., 1988; Jacobson
et al., 1989). The UL39 gene of cytomegalovirus has also been
shown to be a pathogenic determinant despite lacking any RR
enzymatic activity (Lembo et al., 2004). Thus, the UL39 gene being
a determinant of cross-species neuropathogenicity of HVP2 is
consistent with previous studies on HSV and CMV.
Unlike the large subunit of cellular dimeric RRs, the large RR
subunit polypeptides of herpesviruses have a large N-terminal
domain unrelated to other known proteins (Conner et al., 1994b;
Lembo and Brune, 2009). The RR active site, RR consensus motif,
and other RR associated functions are located in the conserved
C-terminal domain of the UL39 protein suggesting that the
N-terminal region does not function in RR enzymatic activity. Like
HSV UL39 mutants, HVP2ap strains replicate slightly less well in
densely packed, non-dividing Vero cells and exhibit abortive
replication in primary murine cells (Rogers et al., 2007). Previous
studies have also demonstrated that while HVP2ap strains can
replicate in the skin of infected mice, they are less efﬁcient than
HVP2nv strains at invading the CNS and spreading within it
(Rogers et al., 2009). The results of experiments presented here
indicate that the UL39 gene is responsible for this difference in
lethal neurovirulence of HVP2 strains in mice. Furthermore, the
strongly conserved nature of the C-terminal region of the HVP2
UL39 ORF among all strains suggests that the N-terminal region
likely determines the ability to replicate in primary murine cells
Fig. 6. UL39 determines the ability of HVP2 to replicate efﬁciently in primary murine cells but not suppression of IFN-β response. The ability of UL39 recombinants to
replicate in primary murine cells was assessed by infecting conﬂuent PMDF cultures at an MOI¼0.01 PFU/cell and quantitation of infectious virus at 96 h PI by plaque assay
on Vero cells (left panel). Neurovirulent virus carrying the UL39ap ORF (nAn) or with the UL39 ORF deleted (nFn) produced signiﬁcantly less infectious virus than the parental
wild-type or revertant viruses, while apathogenic virus carrying the UL39nv ORF (aNa) produced signiﬁcantly higher levels of infectious virus than the apathogenic wild-type,
revertant (aAa) or UL39 deletion virus (aFa). To assess the role of UL39 in suppressing the IFN-β response, PMDF cultures were infected at an MOI¼0.4 PFU/cell and IFN-β
present in the extracellular medium assayed by ELISA at 24 h PI (right panel). The background of the recombinant viruses but not the UL39 ORF correlated with the ability to
effectively suppress the IFN-β response. In each graph, the background of each set of viruses (WT, revertant, UL39 deletion and two UL39 recombinants) are indicated below
the graph. Data were analyzed using a two-way ANOVA and compared to the parental virus with signiﬁcance set to 0.05. Asterisks denote signiﬁcant differences between
recombinants and their respective parental wild type virus.
D. Black et al. / Virology 452-453 (2014) 86–94 91
and to efﬁciently invade and replicate within the CNS of mice.
Further experiments are required to test this.
Previous studies on the ability of HVP2 strains to replicate in
primary murine cells found that efﬁcient replication correlated
with the ability of the virus to suppress an IFN-β response; an IFN-
β response was induced by HVP2ap infection while HVP2nv strains
effectively suppressed any such response (Rogers et al., 2009). This
suggested that the innate immune response, in particular the IFN-β
response, was important in determining the ability of HVP2 to
cause serious CNS disease. However, the results of experiments
presented here with UL39 mutants are not entirely inconsistent
with this prediction. The UL39 ORF (ap vs. nv) is not solely
responsible for suppressing the IFN-β response, although it does
apparently play some role as evidenced by the low level but
consistent IFN-β response induced following infection with the
HVP2nv nFn mutant. Since deletion of the UL39 ORF from either
HVP2 subtype results in a failure to sustain replication in primary
murine cells, the UL39 ORF/protein is clearly required for this.
While the nFn deletion mutant did allow a low IFN-β response,
HVP2ap mutants carrying the UL39nv ORF did not, suggesting that
some function of UL39 unrelated to complete suppression of the
IFN-β response determines the ability of the virus to replicate in
primary murine cells and invade/spread within the CNS.
The HVP2 UL39 protein is closely related to the homologous
HSV protein, and homologs of all domains and speciﬁc AA residues
associated with various functions or motifs in HSV are readily
evident in the HVP2 protein. If RR enzymatic activity were to
impart on the virus the ability to replicate in neurons, the lack of
RR activity in HVP2ap isolates would be a ready explanation for
their lack of neurovirulence. However, the vast majority of AA SSDs
in the HVP2 UL39 are located in the N-terminal region of the
protein, only two conserved substitutions being present within the
C-terminal domain where RR enzymatic activity has been loca-
lized. Also, both HVP2ap and HVP2nv isolates are equally patho-
genic in the natural baboon host (Rogers et al., 2005). This
suggests that the N-terminal domain of the HVP2 UL39 protein
in some way affects neurovirulence of HVP2 in mice, likely
independently of RR enzymatic activity. Furthermore, the lack of
any detectable pathogenic difference of HVP2 isolates in their
natural baboon host suggests that whatever mechanism is
involved in determining neurovirulence of HVP2 in mice is a host
species-speciﬁc function, and it is difﬁcult to see how RR enzy-
matic activity would be species-speciﬁc. Additional studies are
clearly needed to dissect the mechanism of HVP2 UL39-
determined neurovirulence.
While much effort has gone into associating a critical neuro-
virulence function with the large N-terminal region of the HSV
UL39 protein, none has yet been identiﬁed. Initially, UL39 was
thought to have protein kinase (PK) activity (Smith and Aurelian,
1997), but further research established that the UL39 protein does
not itself have PK activity but rather is an excellent PK substrate
(Conner, 1999). The HSV UL39 protein is cleaved in infected cells
(Conner et al., 1994a, 1994b; Smith and Aurelian, 1997) but the
signiﬁcance of this is unknown. Sequence analysis indicates that
the N-terminal region of the UL39 protein has what could be
a membrane signal sequence and a transmembrane domain, and
the UL39 protein has been detected associated with cellular
membranes as well as the nucleus (Smith et al., 1994), but again
the signiﬁcance of this remains unknown. There is a RIP homotypic
interaction motif (RHIM) present near the N-terminus that allows
the UL39 protein of CMV to interact with receptor-interacting
protein 1 (RIP1), thereby acting as a RIP1 inhibitor and impeding
RIP1-dependent processes such as NF-κB activation after TNFα or
Toll-like receptor 3 stimulation and activation of p38 mitogen-
activated protein kinase (MAPK) and caspase-independent pro-
grammed cell death (Mack et al., 2008; Upton et al., 2008).
Although recent studies have demonstrated that the HSV UL39
protein has chaperone-like activity and blocks TNFα-induced apop-
tosis (Chabaud et al., 2003, 2007), the overall function of the large
N-terminal region of UL39 in neurovirulence remains unresolved.
The HVP2-mouse system provides an ideal model with which both
the function of the N-terminal region of the UL39 protein and the




The origins of HVP2 isolates have been reported elsewhere, as
has their neurovirulence in mice (Eberle et al., 1995, 1998; Rogers
et al., 2003). HVP2nv strains OU1-76 and X313 and HVP2ap strains
OU2-5 and A951 were used for most experiments. Virus stocks
were grown and titrated in Vero cells. Some experiments utilized
primary mouse dermal ﬁbroblast (PMDF) cell cultures prepared
from mouse skin as previously described (Rogers et al., 2007).
Genomic DNA sequencing
Viral genome sequences were determined as described
(Severini et al., 2013; Tyler and Severini, 2006; Tyler et al., 2011).
Brieﬂy, initial sequencing was performed on a Genome Sequencer
20 (Roche) using the manufacturer0s shotgun sequencing protocol.
Sequencing was performed to an approximate depth of coverage
of 40 and the data assembled with the GS De Novo Assembler
(Roche). To ﬁll sequence gaps, a conventional plasmid based
shotgun library was prepared using the TOPO Shotgun Subcloning
Kit (Invitrogen). Plasmid DNA was end sequenced, and clones of
interest fully sequenced. Gaps in regions not covered by spanning
clones were closed using conventional PCR. The UL39 ORFs of a
number of HVP2 isolates were determined by direct sequencing of
PCR products. All sequence data have been submitted to the
Genbank database (UL39 sequences: accession nos. KF790618–
KF790630; HVP2 genome sequences accession nos. KF908239–
KF908244).
To identify regions of the HVP2 genome potentially associated
with neurovirulence, open reading frames (ORFs) were aligned
and nucleotide differences were classiﬁed as either subtype-
speciﬁc differences (SSDs) (the same in all HVP2ap isolates but
different from HVP2nv isolates) or as isolate-speciﬁc differences
(present in one or more isolates but not correlating with the
neurovirulence phenotype). SSDs were further subdivided into
those that resulted in a no change in amino acid (AA) sequence, a
conservative AA change, or a non-conservative AA change. To
assess the distribution of types of sequence differences across the
HVP2 genome, ORF variation scores were calculated by assigning
SSDs that resulted in no AA change a value of 0, a conservative AA
change a value of 1, a non-conservative change a value of 2, and
those resulting in an insertion/deletion a value of 2. To account for
the varying size of ORFs, the total score for each ORF was divided
by the ORF size (number of AAs) and multiplied by 100.
Construction of recombinant viruses
Viral DNA was puriﬁed from infected cells on NaI gradients as
described (d0Offay et al., 1993; Walboomers and Schegget, 1976).
Viral DNA from an HVP2nv and an HVP2ap strain (2.5 mg each) was
digested for 1 h with Xba1. All HVP2 strains have a single Xba1 site
located in the UL33 ORF. After digestion, viral DNAs were mixed at
a 1:1 ratio, precipitated, resuspended in 10 mM Tris/0.1 mM EDTA,
and 5 mg transfected into subconﬂuent Vero cells using the
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Geneporter reagent (Genlantis, San Diego, CA). When CPE was
evident (24–36 h post-transfection) cell cultures were subjected to
2 freeze/thaw cycles, clariﬁed by centrifugation at 14,000g for 15 s,
the supernatant diluted and plated onto Vero cell monolayers,
incubated at 37 1C for 1 h, and cultures overlaid with medium
containing 1% methylcellulose. Once plaques developed (48 h),
individual plaques were picked and inoculated onto Vero cells.
When CPE was complete, infected cultures were subjected to
2 freeze/thaw cycles, clariﬁed by centrifugation, the supernatant
saved as stock, and DNA extracted from the pellet using DNAzol
per the manufacturer0s instructions (Molecular Research Center,
Inc., Cincinnati, OH). Using primers located on either side of the
unique Xba1 site in the UL33 ORF, sequence spanning the Xba1 site
was ampliﬁed by PCR and sequenced, allowing HVP2nv/ap recom-
binants to be identiﬁed based in single nucleotide sequence
differences that distinguished the two parental viruses. Recombi-
nants were further characterized by PCR/sequencing to determine
which parental virus the RL2 (ICP0), US4, UL5 and UL51 genes
were derived from. Additional mapping of the UL33–UL56 region
of some recombinants was performed using PCR/sequencing with
primers located at approximately 5 kbp intervals.
Gene-speciﬁc recombinants were constructed using a GFP
expression cassette insertion/replacement approach as previously
described (Rogers et al., 2009). Brieﬂy, sequences ﬂanking the
UL39 ORF 50 (1.7 kbp) and 30 (2.0 kbp) as well as the UL39 ORF
(2.85 kbp) were ampliﬁed by high ﬁdelity PCR incorporating
unique restriction sites at their termini. The 50 and 30 ﬂanking
sequences were cloned into pLitmus28i and a ﬂuorescent protein
(GFP or RFP) expression cassette (Black et al., 2002) was inserted
between the two ﬂanking sequences. To delete the UL39 ORF the
construct was transfected into Vero cells, the cultures infected
with virus 24 h later, and ﬂuorescent viral plaques picked and
plaque puriﬁed. Gene-speciﬁc UL39 recombinants were sub-
sequently produced by inserting a UL39 ORF between the two
ﬂanking sequences, the construct transfected into cells, cells
infected with a ﬂuorescent UL39-deletion virus, non-ﬂuorescent
plaques picked, and the virus then plaque puriﬁed. All mutant
viruses were sequenced across the entire region (50 ﬂanking, ORF,
and 30 ﬂanking) to conﬁrm the sequence integrity of the region.
Mouse inoculations
All animal experiments were reviewed and approved by the
OSU IACUC. Mice were inoculated to assess neurovirulence of
viruses as described (Rogers et al., 2003). Brieﬂy, the left ﬂank of
10–12 g Balb/c mice was shaved, the skin lightly scariﬁed, and 105
PFU of virus applied. Mice were observed for clinical symptoms of
neurological infection for 2 weeks, and any mice showing signs of
serious CNS involvement were humanely euthanized.
Statistical analyses
Statistical analyses were performed using the software pro-
gram SigmaPlot (version 11.0, Systat Software Inc., Chicago, IL). The
effects of viral strain and of recombination on viral titer or IFN-β
production were each tested by a two-way analysis of variance
(ANOVA). Viral titers were log10 transformed to meet normality
assumptions. Further comparisons of recombinants vs. the wild-
type virus were performed using the Holm–Sidak multiple com-
parison procedure with the overall signiﬁcant level set to 0.05.
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